Artificial cell microcapsules containing live bacterial cells and activated charcoal for managing renal failure creatinine: preparation and in-vitro analysis

Open access

Abstract

Activated charcoal was microencapsulated with Lactobacillus acidophilus 314 previously adapted for urea uptake. The creatinine removal capacity of this combination microcapsule was evaluated in-vitro in media simulating the small intestine. Results show that microcapsules containing both activated charcoal and L. acidophilus 314 demonstrated potential for decreasing creatinine. Interestingly, when co-encapsulating both activated charcoal and L. acidophilus 314 a smaller decrease in creatinine was observed than when encapsulating them separately. However, co-encapsulated microcapsules were more stable in various parts of the gastrointestinal system and survived longer in storage. These results suggest the feasibility of using microcapsules containing activated charcoal and probiotic bacteria as oral adjuvants for creatinine removal and provides a theoretical model for the use of these microcapsules to remove any unwanted metabolite.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Varma R. R. Garrick J. McClung and W. H. Frishman. 2005. Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease. Cardiology in review 13: 98-107.

  • 2. Chow K. M. C. C. Szeto C. B. Leung B. C. Kwan M. C. Law and P. K. Li. 2005. A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 25: 374-379.

  • 3. Stewart C. L. S. N. Acker L. L. Pyle A. Kulungowski M. Cadnapaphornchai J. L. Bruny and F. Karrer. 2016. Factors associated with peritoneal dialysis catheter complications in children. Journal of pediatric surgery 51: 159-162.

  • 4. Ratajczak A. M. Lange-Ratajczak A. Bobkiewicz and A. Studniarek. 2017. Surgical Management of Complications with Perito-neal Dialysis. Seminars in Dialysis 30: 63-68.

  • 5. Wang L.-J. and C.-K. Che. 2012. The Psychological Impact of Hemodialysis on Patients with Chronic Renal Failure.

  • 6. Depner T. A. and L. D. Cowgill. 2014. Can oral therapy reduce uremic toxins? Clin J Am Soc Nephrol 9: 1513-1515.

  • 7. Jain P. S. Shah R. Coussa and S. Prakash. 2009. Potentials and limitations of microorganisms as renal failure biotherapeutics. Biologics 3: 233-243.

  • 8. Vaziri N. D. J. Yuan M. Khazaeli Y. Masuda H. Ichii and S. Liu. 2013. Oral Activated Charcoal Adsorbent (AST-120) Ameliorates Chronic Kidney Disease-Induced Intestinal Epithelial Barrier Disruption. American Journal of Nephrology 37: 518-525.

  • 9. Dhondt A. R. Vanholder W. Van Biesen and N. Lameire. 2000. The removal of uremic toxins. Kidney International 58: S47-S59.

  • 10. Clark J. E. J. Y. Templeton 3rd and C. D. Mc. 1962. Perfusion of isolated intestinal loops in the management of chronic renal failure. Transactions - American Society for Artificial Internal Organs 8: 246-251.

  • 11. Parisi R. 1969. Management of chronic renal failure by isolated jejunal loop perfusion. British journal of urology 41: 603-604.

  • 12. Goto S. K. Yoshiya T. Kita H. Fujii and M. Fukagawa. 2011. Uremic toxins and oral adsorbents. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis the Japanese Society for Apheresis the Japanese Society for Dialysis Therapy 15: 132-134.

  • 13. Sato E. D. Saigusa E. Mishima T. Uchida D. Miura T. Morikawa-Ichinose K. Kisu A. Sekimoto R. Saito Y. Oe Y. Matsumoto Y. Tomioka T. Mori N. Takahashi H. Sato T. Abe T. Niwa and S. Ito. 2017. Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques. Toxins (Basel) 10: 19.

  • 14. Abidin M. N. Z. P. S. Goh A. F. Ismail N. Said M. H. D. Othman H. Hasbullah M. S. Abdullah B. C. Ng S. H. S. A. Kadir and F. Kamal. 2018. Highly adsorptive oxidized starch nanoparticles for efficient urea removal. Carbohydrate Polymers 201: 257-263.

  • 15. Chandy T. and C. P. Sharma. 1998. Activated charcoal microcapsules and their applications. Journal of biomaterials applications 13: 128-157.

  • 16. Sparks R. E. N. S. Mason P. M. Meier M. H. Litt and O. Lindan. 1971. Removal of uremic waste metabolites from the intestinal tract by encapsulated carbon and oxidized starch. Transactions-American Society for Artificial Internal Organs 17: 229-238.

  • 17. Prakash S. and T. M. S. Chang. 1996. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nature Medicine 2: 883-887.

  • 18. Bhatia A. P. Rana A. Sharma R. Singla and M. K. Randhawa. 2012. Preparation characterization and hypocholesterolemic effect of sodium alginate encapsulated lab isolate. Journal of Microbiology and Biotechnology Research 2: 741-746.

  • 19. Solga S. F. 2003. Probiotics can treat hepatic encephalopathy. Medical Hypotheses 61: 307-313.

  • 20. Iqbal U. H. S. Westfall and S. Prakash. 2018. Novel microencapsulated probiotic blend for use in metabolic syndrome: design and in-vivo analysis. Artificial cells nanomedicine and biotechnology 46: S116-s124.

  • 21. Westfall S. N. Lomis and S. Prakash. 2019. A novel synbiotic delays Alzheimer’s disease onset via combinatorial gut-brain-axis signaling in Drosophila melanogaster. PLOS ONE 14: e0214985.

  • 22. Prakash S. and T. M. Chang. 1995. Preparation and in vitro analysis of microencapsulated genetically engineered E. coli DH5 cells for urea and ammonia removal. Biotechnology and bioengineering 46: 621-626.

  • 23. Dehghani H. F. Heidari H. Mozaffari-Khosravi N. Nouri-Majelan and A. Dehghani. 2016. Synbiotic Supplementations for Azotemia in Patients With Chronic Kidney Disease: a Randomized Controlled Trial. Iranian journal of kidney diseases 10: 351-357.

  • 24. Firouzi S. B.-N. Mohd-Yusof H.-A. Majid A. Ismail and N.-A. Kamaruddin. 2015. Effect of microbial cell preparation on renal profile and liver function among type 2 diabetics: a randomized controlled trial. BMC Complement Altern Med 15: 433-433.

  • 25. Natarajan R. B. Pechenyak U. Vyas P. Ranganathan A. Weinberg P. Liang M. C. Mallappallil A. J. Norin E. A. Friedman and S. J. Saggi. 2014. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res Int 2014: 568571-568571.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 52 52 52
PDF Downloads 30 30 30